Expression of insulin-like growth factor II in chronic hepatitis B, liver cirrhosis, and hepatocellular carcinoma.
In this study we investigated the expression of insulin-like growth factor II (IGf-II) to explain a role for this growth factor in concert with hepatitis B virus (HBV) involvement in the development of hepatocellular carcinoma (HCC) from chronic hepatitis type B (CAH-B) and liver cirrhosis (LC). The expressions of IGF-II and HBsAg were tested in tissue samples from 38 patients with CAH-B, 32 with LC, and 31 with HCC, by immunohistochemical staining using monoclonal anti IGF-II and anti HBs. All patients were seropositive for the presence of HBsAg. The expression of IGF-II was observed in 30 out of 32 (93.8%) LC and all 31 (100%) HCC tissue samples tested. IGF-II was expressed in most hepatocytes of regenerating nodules and in tumorous as well as nontumorous cells of HCC tissues. Neither normal liver tissues nor CAH-B tissue samples expressed IGF-II. HBsAg was expressed in 34 out of 38 (89.5%) CAH-B, 24 out of 32 (75%) LC and 13 out of 31 (41.9%) HCC tissue samples. The expression sites of HBsAg were not correlated with those of IGF-II in any tissue samples tested. The present study indicates that IGF-II plays a role in cell proliferation of regenerating nodules as well as in the development of hepatocellular carcinomas. In addition, there was no direct evidence of HBV involvement in the overexpression of this growth factor.